Cell cycle aberrations in the pathogenesis of squamous cell carcinoma of the uterine cervix

Gynecologic Oncology

Volumn 82, Issue 2, 2001, Pages 238-246

  Clarke, B ^a   Chetty, R ^a  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN A; CYCLIN B; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN E; CYCLINE; DIHYDROFOLATE REDUCTASE; DNA; DNA POLYMERASE; ONCOPROTEIN; PROTEIN MDM2; PROTEIN P130; PROTEIN P16; PROTEIN P19; PROTEIN P21; PROTEIN P27; PROTEIN P53; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR E2F;

APOPTOSIS; CANCER INHIBITION; CARCINOGENESIS; CELL CYCLE; CELL IMMORTALIZATION; GENE MUTATION; HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; WART VIRUS;

EID: 0034897124     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.2001.6306     Document Type: Review

References (107)

1. The hallmarks of cancer
2. G1 progression: Cycling on cue
3. Cyclins and oncogenesis
4. Principles of CDK regulation
5. Cyclin D1 and human neoplasia
6. Cyclins and cell cycle checkpoints
7. Mutation of cell cycle regulators: Biological and clinical implications for human neoplasia
8. 1-phase progression
9. Cell cycle regulators: Mechanisms and their role in aetiology, prognosis, and treatment of cancer
10. The retinoblastoma protein and cell cycle control
11. Cyclin A-kinase regulation of E2F-1 DNA binding function underlies suppression of an S phase checkpoint
12. Cdk2 kinase is required for entry into mitosis as a positive regulator of Cdc2-cyclin B kinase activity
13. Growth arrest by the cyclin dependent kinase inhibitor p27Kip 1 is abrogated by c-myc
14. Cyclin D1 protein expression and function in human breast cancer
15. Correlation of cyclin D1 and Rb gene expression with apoptosis in invasive breast cancer
16. Cyclin D1 and retinoblastoma protein expression in oesophageal squamous cell carcinoma
17. Altered expression of the cyclin D1 and retinoblastoma genes in human esophageal cancer
18. Correlation between G1 cyclins and HPV in uterine cervix
19. Aberrant expression of the cell cycle associated proteins TP53, MDM2, p27, cdk4, cyclin D1, RB and EGFR in cervical carcinomas
20. DNA tumor virus oncoproteins and retinoblastoma gene mutations share the ability to relieve the cell's requirement for cyclin D1 function in G1
21. Cyclin D1 expression is regulated by the retinoblastoma protein
22. The retinoblastoma protein and the regulation of cell cycling
23. Physical interaction of the retinoblastoma protein with human D cyclins
24. Patterns of DNA amplification at band q13 of chromosome 11 in human breast cancer
25. Loss of heterozygosity and amplification on chromosome 11 q in human ovarian cancer
26. Amplification at chromosome 11q13 in transitional cell tumors of the bladder
27. Centrocytic lymphoma: A B cell non-Hodgkin's lymphoma characterized by chromosome 11 bcl-1 and PRAD1 rearrangements
28. Abnormalities in the PRAD1 (CYCLIN D1/BCL-1) oncogene are frequent in cervical and vulvar squamous cell carcinoma cell lines
29. Cyclin D1 gene expression in human cervical neoplasia
30. Dual cyclin-binding domains are required for p107 to function as a kinase inhibitor
31. p130 and p107 use a conserved domain to inhibit cellular cyclin-dependent kinase activity
32. Regions of human papillomavirus type 16 E7 oncoprotein required for immortalisation of human keratinocytes
33. Human papillomavirus E7 oncoproteins bind a single form of cyclin E in a complex with cdk2 and p107
34. Specific regulation of E2F family members by cyclin-dependent kinases
35. pRb, p107, and the regulation of the E2F transcription factor
36. Tumor induction and tissue atrophy in mice lacking E2F-1
37. Control of the cell cycle and apoptosis
38. Deletions of the cyclin dependent kinase 4 inhibitor gene in multiple human cancers
39. Homozygous loss of cyclin dependent kinase 4-inhibitor (p16) gene in human leukemias
40. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma
41. Frequent somatic mutation of the MTS1/CDK4I (multiple tumor suppressor/cyclin-dependent kinase 4 inhibitor) gene in esophageal squamous cell carcinoma
42. p16 (CDK2/cyclin-dependent kinase 4 inhibitor/multiple tumor suppressor-1) gene is not altered in uterine cervical carcinomas or cell lines
43. Underexpression of cyclin-dependent kinase (CDK) inhibitors in cervical carcinoma
44. In situ detection of the hypermethylation-induced inactivation of the p 16 gene as an early event in oncogenesis
45. Aberrant methylation of p16 (INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis
46. Infection with human immunodeficiency virus type 1 upregulates DNA methyltransferase, resulting in de novo methylation of the gamma interferon (IFN-gamma) promoter and subsequent downregulation of IFN-gamma production
47. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest
48. Tumor surveillance via the ARF-p53 pathway
49. Current concepts in neuro-oncology: The cell cycle
50. Developmental control of the G1 to S transition in Drosophila: Cyclin E is a limiting downstream target of E2F
51. E2F-induced S phase requires cyclin E
52. S-Phase entry upon ectopic expression of G1 cyclin-dependent kinases in the absence of retinoblastoma protein phosphorylation
53. Cyclin E-induced-S phase without activation of the pRb/E2F pathway
54. Myc and Ras collaborate in inducing accumulation of active cyclin E/Cdk2 and E2F
55. Redundant cyclin overexpression and gene amplification in breast cancer cells
56. Stepwise abnormality of sex steroid hormone receptors, tumor suppressor gene products (p53 and Rb), and cyclin E in uterine endometrioid carcinoma
57. Evidence for keratinocyte immortalization in high-grade squamous intraepithelial lesions of the cervix with high-risk human papillomavirus
58. Expression of cyclin E in gynecologic malignancies
59. The human papillomavirus E7 oncoprotein can uncouple cellular differentiation and proliferation in human keratinocytes by abrogating p21Cip1-mediated inhibition of cdk2
60. Papilloma-virus sequences integrate near cellular oncogenes in some cervical carcinomas
61. Association of p27Kip1, cyclin E and c-myc expression with progression and prognosis in HPV-positive cervical neoplasms
62. Deregulated cyclin E induces chromosome instability
63. Cyclin dependent kinase control of centrosome duplication
64. A role for Cdk2 kinase in negatively regulating DNA replication during S phase of the cell cycle
65. Regulated chromosomal DNA replication in absence of a nucleus
66. Keeping the centrosome cycle on track. Genome stability
67. Cyclin E: A better prognostic marker for breast cancer than cyclin D?
68. Cyclin E expression and proliferation in breast cancer
69. Localization and expression of p27kip1 in multistage colorectal carcinogenesis
70. Effects of cyclin E overexpression on cell growth and response to TGF-B depend on cell context and p27kip1 expression
71. Overexpression of cyclin E in the HC 11 mouse mammary epithelial cell line is associated with growth inhibition and increased expression of p27(Kip1)
72. Anchorage independent transcription of the cyclin A gene induced by the E7 oncoprotein of human papillomavirus type 16
73. Inactivation of the CDK inhibitor p27KIP1 by the human papillomavirus type 16 E7 oncoprotein
74. E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway
75. Decreased levels of the cell-cycle inhibitor p27KIP1 protein: Prognostic implications in primary breast cancer
76. Ordering of S phase and M phase in the cell cycle
77. A link between cyclin A expression and adhesion dependent cell cycle progression
78. Different expression patterns of cyclins A, D1 and E in human colorectal cancer
79. Cyclins as markers of tumor proliferation: Immunocytochemical studies in breast cancer
80. Immunohistochemical detection of sex steroid receptors, cyclins, and cyclin-dependent kinases in the normal and neoplastic squamous epithelia of the uterine cervix
81. Mitosis in transition
82. p53 regulates a G2 checkpoint through cyclin B1
83. WAF1/C1P1 is induced in p53-mediated G1 arrest and apoptosis
84. p53 controls both the G2/M and the G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts
85. P53 point mutations in cervical carcinogenesis: Low frequency and lack of correlation with human papillomavirus status
86. The state of p53 in primary cervical carcinomas and its effects in human papilomavirus-immortalized human cervical cells
87. Presence and persistence of HPV infection and p53 mutation in cancer of the cervix uteri and vulva
88. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53
89. Association of human papillomavirus types 16 and 18 E6 proteins with p53
90. p53 antigen in cervical condylomata, intraepithelial neoplasia, and carcinoma: Relationship to HPV infection and integration
91. Variations in immunohistochemical detection of p53 protein overexpression in cervical carcinomas with different antibodies and methods of detection
92. p53 expression and genetic evidence for viral infection in intraepithelial neoplasia of the uterine cervix
93. Immunohistochemical analysis of p53 protein overexpression in normal, premalignant and malignant tissues of the cervix uteri
94. p53 independent expression of p21waf1/cip1 in preinvasive and invasive squamous neoplasms of the uterine cervix
95. Cervical squamous carcinomas with immunodetectable p53 frequently contain HPV
96. HPV and p53 in cervical cancer
97. Immunohistochemical analysis of p53 in gynecologic tumors
98. Genetic alterations of the TP53 gene, p53 protein expression and HPV infection in primary cervical carcinomas
99. p53 expression in Reed-Sternberg cells of Hodgkin's disease
100. p53 mutations in colorectal cancer
101. Increased expression of mutant forms of p53 oncogene in primary lung cancer
102. A conformational hypothesis for suppressor and promoter functions of p53 in cell growth control and in cancer
103. Immunohistochemical expression of mdm2 and p21waf1 in invasive cervical cancer: Correlation with p53 protein and high risk HPV infection
104. Growth inhibitory concentrations of EGF induce p21 (WAK1/Cip1) and alter cell cycle control in squamous carcinoma cells
105. Induction of differentiation in human promyelocytic HL-60 leukemia cells activates p21 WAF1/CIP1 expression in absence of p53
106. Inhibition of CDK activity and PCNA-dependent DNA replication by p21 is blocked by interaction with the HPV-16 E7 oncoprotein